Dimensional Fund Advisors LP Boosts Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Dimensional Fund Advisors LP lifted its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMAFree Report) by 1.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,715,420 shares of the company’s stock after acquiring an additional 21,420 shares during the quarter. Dimensional Fund Advisors LP owned 3.11% of Olema Pharmaceuticals worth $24,069,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Vivo Capital LLC lifted its stake in Olema Pharmaceuticals by 39.9% in the 3rd quarter. Vivo Capital LLC now owns 1,873,704 shares of the company’s stock valued at $23,140,000 after buying an additional 534,433 shares in the last quarter. MPM Bioimpact LLC lifted its stake in Olema Pharmaceuticals by 301.7% in the 3rd quarter. MPM Bioimpact LLC now owns 1,857,681 shares of the company’s stock valued at $22,942,000 after buying an additional 1,395,181 shares in the last quarter. Vanguard Group Inc. lifted its stake in Olema Pharmaceuticals by 2.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,710,307 shares of the company’s stock valued at $21,122,000 after buying an additional 36,785 shares in the last quarter. Polar Capital Holdings Plc purchased a new position in Olema Pharmaceuticals in the 3rd quarter valued at about $9,262,000. Finally, Victory Capital Management Inc. lifted its stake in Olema Pharmaceuticals by 879.6% in the 4th quarter. Victory Capital Management Inc. now owns 621,527 shares of the company’s stock valued at $8,720,000 after buying an additional 558,077 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ OLMA opened at $11.76 on Tuesday. The company has a 50 day simple moving average of $10.28 and a 200-day simple moving average of $12.17. The company has a market capitalization of $657.74 million, a P/E ratio of -5.82 and a beta of 2.05. Olema Pharmaceuticals, Inc. has a 1 year low of $5.64 and a 1 year high of $17.79.

Olema Pharmaceuticals (NASDAQ:OLMAGet Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). As a group, research analysts expect that Olema Pharmaceuticals, Inc. will post -2.37 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on OLMA shares. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday, May 15th. The Goldman Sachs Group began coverage on shares of Olema Pharmaceuticals in a report on Tuesday, April 2nd. They issued a “buy” rating and a $24.00 price objective for the company. Finally, Capital One Financial reiterated an “overweight” rating on shares of Olema Pharmaceuticals in a report on Thursday, February 22nd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Olema Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $22.00.

Read Our Latest Research Report on OLMA

Insider Transactions at Olema Pharmaceuticals

In other news, Director Cyrus Harmon sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $9.51, for a total transaction of $142,650.00. Following the completion of the sale, the director now owns 811,283 shares in the company, valued at approximately $7,715,301.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 40,000 shares of company stock worth $416,650 in the last 90 days. Insiders own 19.40% of the company’s stock.

About Olema Pharmaceuticals

(Free Report)

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

Recommended Stories

Want to see what other hedge funds are holding OLMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Olema Pharmaceuticals, Inc. (NASDAQ:OLMAFree Report).

Institutional Ownership by Quarter for Olema Pharmaceuticals (NASDAQ:OLMA)

Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.